JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.